Five months without disease progression—that's the difference this trial found
When the immune system's trained defenses fail against advanced kidney cancer, oncologists have long faced an unanswered question: which second-line treatment to reach for next. A Phase II trial presented at the European Society for Medical Oncology Congress in October has begun to answer that question, finding that a combination of lenvatinib and everolimus extended progression-free survival by more than five months compared to cabozantinib alone among ninety patients whose cancers had resisted immunotherapy. In a field where head-to-head comparisons are rare, this evidence offers something medicine prizes deeply — not just proof that something works, but proof of what works better.
- For patients with metastatic kidney cancer that has outpaced immunotherapy, every additional month without disease progression represents a different quality of life — and the LenCabo trial found more than five of those months separating the two treatments.
- Until now, oncologists choosing between lenvatinib-everolimus and cabozantinib were navigating without a map — no randomized trial had ever placed these two common second-line options directly against each other.
- The combination therapy held disease progression at bay for a median of 15.7 months versus 10.2 months for cabozantinib, and fewer patients in the combination group saw their cancer worsen at all — 62.5 percent compared to 76 percent.
- Presented at ESMO by MD Anderson's Dr. Andrew Hahn, the findings are already being framed as a guide for treatment sequencing decisions in one of oncology's most difficult clinical crossroads.
- The trial's rarity — comparative rather than placebo-controlled — gives its results unusual weight, offering the kind of direct evidence that can shift clinical practice rather than simply add to a list of options.
When kidney cancer spreads and stops responding to immunotherapy, oncologists face a consequential choice with little guidance: which second-line drug to prescribe next. The LenCabo trial, presented at the European Society for Medical Oncology Congress in October, was designed specifically to answer that question — the first randomized head-to-head comparison of two treatments commonly used at this juncture.
Researchers from MD Anderson Cancer Center enrolled ninety patients whose metastatic clear-cell renal carcinoma had progressed despite prior immunotherapy targeting the PD-1 or PD-L1 pathways. Half received a combination of lenvatinib and everolimus; the other half received cabozantinib alone. The results favored the combination clearly: patients on lenvatinib-everolimus went a median of 15.7 months before their cancer advanced, compared to 10.2 months for cabozantinib — a difference of more than five months. Disease progression occurred in 62.5 percent of the combination group versus 76 percent of those on cabozantinib.
Dr. Andrew Hahn, who presented the findings, underscored what makes the trial unusual. Most oncology studies test drugs against placebo or standard care — not directly against a competing regimen. That comparative design gives the LenCabo results particular clinical weight, offering doctors something rare: evidence not just that a treatment works, but that it works better than the alternative they were already using.
For patients whose first line of defense has failed, the implications are immediate. The findings suggest lenvatinib-everolimus may be the stronger second-line choice, and the data now exists to help guide that decision with confidence rather than convention.
At the European Society for Medical Oncology Congress in October, researchers from MD Anderson Cancer Center presented findings that could reshape how doctors treat kidney cancer patients whose tumors have stopped responding to immunotherapy. The trial, called LenCabo, directly compared two drugs commonly prescribed at this critical juncture: a combination of lenvatinib and everolimus against cabozantinib alone. What they found matters because until now, no one had run a head-to-head test to see which actually worked better.
Kidney cancer that has spread beyond the organ—metastatic clear-cell renal carcinoma—typically begins with immunotherapy drugs that train the immune system to attack cancer cells. But for some patients, the cancer adapts and grows anyway. When that happens, oncologists have traditionally turned to one of two second-line options. The new trial enrolled ninety patients whose disease had progressed despite prior immunotherapy and randomly assigned them to receive either the lenvatinib-everolimus combination or cabozantinib.
The results tilted clearly in one direction. Patients on the combination therapy went a median of 15.7 months before their cancer progressed, compared to 10.2 months for those receiving cabozantinib—a difference of more than five months. When researchers looked at how many patients experienced disease progression, 62.5 percent of the combination group saw their cancer worsen, versus 76 percent in the cabozantinib group. These numbers matter because they represent the difference between more time living without visible tumor growth, more time before the next treatment becomes necessary, more time with a different quality of life.
Dr. Andrew Hahn, the assistant professor of genitourinary medical oncology who presented the data, emphasized that this was the first randomized trial to directly pit these two regimens against each other. "These findings offer insights into treatment sequencing and the importance of generating head-to-head data to guide clinical decisions," he said. The trial enrolled patients who had received one or two prior treatments, all of which included at least one immunotherapy targeting the PD-1 or PD-L1 pathways—the standard opening move in kidney cancer treatment.
The significance extends beyond the numbers themselves. Oncologists have long faced a fork in the road when immunotherapy fails: which drug to choose next? The trial was specifically designed to answer that question by measuring progression-free survival—the time patients remain free of disease advancement. The lenvatinib-everolimus combination's five-month advantage suggests it may offer more meaningful benefit as a second-line approach, potentially guiding which patients receive which treatment based on what we now know works longer.
For patients facing advanced kidney cancer that has resisted initial immunotherapy, the implications are concrete. The findings suggest that the combination regimen may be the more effective choice when the first line of defense fails. This kind of head-to-head evidence is rare in oncology—most drugs are tested against placebo or standard care, not directly against each other. The LenCabo trial fills that gap, providing the kind of comparative data that can shift clinical practice and help doctors make more informed decisions about which path to take when the first one stops working.
Citas Notables
This is the first randomized trial to directly compare these two commonly used second-line treatments. These findings offer insights into treatment sequencing and the importance of generating head-to-head data to guide clinical decisions.— Dr. Andrew W. Hahn, MD Anderson Cancer Center
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is the first head-to-head comparison? Weren't these drugs already being used as second-line treatments?
They were, but doctors were essentially choosing between them without knowing which actually worked better. It's like having two routes to the same destination and picking one based on habit or side effect profiles, not on which gets you there faster. This trial finally shows which one does.
Five months sounds significant. But for a patient, what does that actually mean in their life?
It means five more months without watching their cancer grow on scans. Five more months before they need to switch treatments again, deal with new side effects, start over psychologically. In advanced cancer, that's substantial—it's the difference between spring and winter.
The trial only had ninety patients. Is that enough to trust these results?
It's a Phase II trial, which is designed to show promise and guide Phase III work, not to be the final word. But ninety patients with a clear difference in progression-free survival is enough to shift clinical thinking, especially when it's the first direct comparison anyone's done.
What happens to patients who were already on cabozantinib when these results came out?
That's the practical question doctors are wrestling with now. Some may switch based on this data. Others might stay put if they're tolerating it well. The trial gives oncologists information; it doesn't mandate a single path for every patient.